News

Analysts Maintain Buy Ratings on Eli Lilly Stock (LLY) as Q1 Earnings Loom
Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ...
Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...
24/7 Wall St. on MSN2d
Eli Lilly Will Be the Next $1 Trillion Stock
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...
Houston Public Media4d
Eli Lilly sues Houston-based compounding pharmacy over alleged ‘knockoff’ obesity, diabetes drugs
Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...
Prediction: Eli Lilly's Newest GLP-1 Drug Will Be a Game-Changer for the Stock
Let's look at why this news could be a game-changer for Eli Lilly and its stock.
Eli Lilly says GLP-1 pill for diabetes and weight loss effective in study, plans to seek FDA approval
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...
The Hill4d
Eli Lilly sues telehealth companies selling compounded Zepbound, Mounjaro
Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against ...
Obesity drug boom has a new pecking order
The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...